Feasibility and outcomes of a third allogeneic hematopoietic stem cell transplantation: a retrospective analysis from the ALWP of the EBMT

Few therapeutic options are available for patients with acute myeloid or lymphoblastic leukemia (AML/ALL) relapsing after a second allogeneic stem cell transplantation (alloSCT2). In selected patients a third allogeneic stem cell transplantation (alloSCT3) has been used, but no detailed analysis is available so far.The European Society for Blood and Marrow Transplantation (EBMT) registry was screened for patients with acute leukemia (AL) who had undergone alloSCT3 from an identical or alternative donor to treat AL in either hematological relapse or disease persistence after alloSCT2 between 2001 and 2018.

Source: Biology of Blood and Marrow Transplantation - February 5, 2021 Category: Hematology Authors: A. Rank, C. Peczynski, M. Labopin, M. Stelljes, C. Simand, G. Helbig, J. Finke, S. Santarone, J. Tischer, A. Lange, M. Mistrik, M. Houhou, C. Schmid, A. Nagler, M. Mohty Source Type: research